Plato Investment Management Ltd Has $1.37 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Plato Investment Management Ltd boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,944 shares of the medical research company’s stock after acquiring an additional 2,836 shares during the period. Plato Investment Management Ltd’s holdings in IQVIA were worth $1,370,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. FMR LLC lifted its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the 3rd quarter worth $147,683,000. JPMorgan Chase & Co. lifted its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB lifted its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV raised its position in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after buying an additional 250,458 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $184.67 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $32.52 billion, a price-to-earnings ratio of 24.62, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $184.06 and a 1-year high of $261.73. The firm’s 50-day moving average price is $198.84 and its two-hundred day moving average price is $214.25.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Bank of America cut their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Morgan Stanley upped their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.